文献速递病毒性肝炎

英国非洲裔患者中直接抗病毒药物治疗及再治疗的现实世界结局

Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.
PubMed 文献 · J Infect Dis · 2022-01-01

该研究纳入233例居住于英国、出生于非洲的丙型肝炎患者,进行病毒基因组测序,其中149例接受直接抗病毒药物治疗或再治疗,总体持续病毒学应答率为93%。治疗失败主要与gt1l和gt4r亚型使用索磷布韦/雷迪帕韦相关,这些亚型携带天然耐药相关变异,且治疗失败与肝细胞癌显著相关。

要点

  • 非洲流行HCV亚型多样性高,DAA总体SVR达93%。
  • gt1l和gt4r亚型对索磷布韦/雷迪帕韦应答不佳。
  • 无准确基因分型时,不推荐雷迪帕韦及其仿制药。

核心结论

  • DAA组合在非洲高HCV多样性背景下仍获高SVR率,但gt1l和gt4r亚型对索磷布韦/雷迪帕韦应答差。

研究设计与样本

  • 研究英国居住、非洲出生患者的DAA疗效,对233例患者进行病毒基因组测序。

主要发现

  • 确定26种已知亚型和5株先前未鉴定分离株的全长基因组序列,覆盖5种HCV基因型。
  • 149例接受DAA治疗或再治疗的患者总体SVR为93%。
  • 治疗失败主要与gt1l和gt4r亚型使用索磷布韦/雷迪帕韦相关,这些亚型含天然耐药相关变异。
  • 治疗失败也与肝细胞癌显著相关。

关键数值与推荐

  • 总体SVR为93%(149例接受DAA治疗/再治疗患者)。
  • gt1l和gt4r亚型使用索磷布韦/雷迪帕韦与治疗失败相关。
  • 无准确基因分型时,雷迪帕韦及其仿制药不应视为推荐治疗选择。

临床怎么用

  • 对非洲来源患者,尤其疑似gt1l或gt4r亚型时,避免使用索磷布韦/雷迪帕韦。
  • 缺乏准确基因分型时,不推荐雷迪帕韦及其仿制药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis C virus (HCV) infection affects 71 million individuals, mostly residing in low- and middle-income countries (LMICs). Direct-acting antivirals (DAAs) give high rates of sustained virological response (SVR) in high-income countries where a restricted range of HCV genotypes/subtypes circulate. METHODS: We studied United Kingdom-resident patients born in Africa to examine DAA effectiveness in LMICs where there is far greater breadth of HCV genotypes/subtypes. Viral genome sequences were determined from 233 patients. RESULTS: Full-length viral genomic sequences for 26 known subtypes and 5 previously unidentified isolates covering 5 HCV genotypes were determined. From 149 patients who received DAA treatment/retreatment, the overall SVR was 93%. Treatment failure was associated primarily with 2 subtypes, gt1l and gt4r, using sofosbuvir/ledipasvir. These subtypes contain natural resistance-associated variants that likely contribute to poor efficacy with this drug combination. Treatment failure was also significantly associated with hepatocellular carcinoma. CONCLUSIONS: DAA combinations give high SVR rates despite the high HCV diversity across the African continent except for subtypes gt1l and gt4r, which respond poorly to sofosbuvir/ledipasvir. These subtypes are widely distributed across Western, Central, and Eastern Africa. Thus, in circumstances where accurate genotyping is absent, ledipasvir and its generic compounds should not be considered as a recommended treatment option.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Aranday-Cortes E, McClure CP, Davis C, et al. Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa. J Infect Dis. 2022. PMID: 33668068. doi:10.1093/infdis/jiab110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。